

Reference number(s)

6764-A

Specialty Guideline Management Unloxcyt

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over the counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Unloxcyt	cosibelimab-ipdl

Indication

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Cutaneous Squamous Cell Carcinoma (CSCC)

Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.

All other indications are considered experimental/investigational and not medically necessary.

Exclusions

Coverage will not be provided for members who have experienced disease progression while on programmed death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor therapy.

Unloxcyt SGM 6764-A P2025.docx

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Coverage Criteria

Cutaneous Squamous Cell Carcinoma (CSCC)

Authorization of 6 months may be granted for treatment of metastatic or locally advanced CSCC when member is not a candadidate for curative surgery or radiation.

Continuation of Therapy

Authorization of 6 months may be granted for continued treatment in members requesting reauthorization for an indication listed in in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

References

1. Unloxcyt [package insert]. Waltham, MA: Checkpoint Therapeutics, Inc.; December 2024.